Earnings Release • Oct 27, 2022
Earnings Release
Open in ViewerOpens in native device viewer
Disclosure 414236
Optomed PlcInside Information27 October 2022 at 15.00, Helsinki Inside information, profit warning: Optomed decreases its full year outlook Optomed decreases its full year 2022 outlook due to uncertainty in China. The Company now expects its full year 2022 revenue to stay on the same level as in 2021. While globally Optomed's sales channels have performed well, uncertainty in the Chinese markets continues, affecting on Optomed's short term revenue prospects. The updated outlook for 2022: “Optomed expects its full year 2022 revenue to stay on the same level as in 2021.” Previously outlook (announced 17 February 2022): “Optomed expects its full year 2022 revenue to grow compared to 2021.” Optomed utilizes three thresholds in relation to its revenue guidance: in Optomed's outlook, the revenue may “grow/decrease significantly”, “grow/decrease” or “stay on the same level”. The Company has set fixed internal percentages to reflect each threshold. Optomed will publish the Interim Report for January-September 2022 on 3 November 2022. Optomed Plc Further enquiries Seppo Kopsala, CEO, [email protected] Sakari Knuutti, CFO, [email protected] Optomed in Brief Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company's products are sold via various sales channels in over 60 countries globally www.optomed.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.